| |
|
"Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. |
| |
|
Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention. |
| |
|
Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction. |
| |
|
Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. |
| |
|
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). |
| |
|
Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. |
| |
|
Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. |
| |
|
Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. |
| |
|
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. |
| |
|
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. |
| |
|
Silicon carbide-coated stents in patients with acute coronary syndrome. |
| |
|
Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. |
| |
|
Soluble CD40 ligand in acute coronary syndromes. |
| |
|
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). |
| |
|
Associations between ST depression, four year mortality, and in-hospital revascularisation in unselected patients with non-ST elevation acute coronary syndromes. |
| |
|
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. |
| |
|
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. |
| |
|
Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. |
| |
|
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. |
| |
|
Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. |
| |
|
Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. |
| |
|
Parasympathetic failure and risk of subsequent coronary events in unstable angina and non-ST-segment elevation myocardial infarction. |
| |
|
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. |
| |
|
"Ischemia-guided" versus "early invasive" strategies in the management of acute coronary syndrome/non-ST-segment elevation myocardial infarction: the interventionalist's perspective. |
| |
|
Prediction of Recurrent Events by D-Dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) Study. |
| |
|
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. |
| |
|
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). |
| |
|
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. |
| |
|
Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. |
| |
|
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective. |
| |
|
Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. |
| |
|
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. |
| |
|
Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. |
| |
|
Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? A serial intravascular ultrasound study. |
| |
|
Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. |
| |
|
Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients? |
| |
|
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. |
| |
|
The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. |
| |
|
C-reactive protein and lesion morphology in patients with acute myocardial infarction. |
| |
|
Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. |
| |
|
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). |
| |
|
A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. |
| |
|
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. |
| |
|
A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes. |
| |
|
Soluble CD40L: risk prediction after acute coronary syndromes. |
| |
|
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. |
| |
|
Renal function and risk stratification in acute coronary syndromes. |
| |
|
Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. |
| |
|
Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. |
| |
|
Early and late effects of clopidogrel in patients with acute coronary syndromes. |
| |
|
Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. |
| |
|
Prognostic value of placental growth factor in patients with acute chest pain. |
| |
| |
 |
